Selected publications and other research output

Publications from the development of affibody-drug conjugates

Zhang J, Rinne SS, Yin W, Leitao CD, Björklund E, Abouzayed A, Ståhl S, Löfblom J, Orlova A, Gräslund T, Vorobyeva A. (2024) Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts. ACS Pharmacol Transl Sci 7, 10, 3228–3240. doi: 10.1021/acsptsci.4c00402.
Zhang J, Bodenko V, Larkina M, Bezverkhnyaya E, Xu T, Liao Y, Abouzayed A, Plotnikov E, Tretyakova M, Yuldasheva F, Belousov MV, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A. (2024) Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation. J Contr Release 370, 468-478. doi: 10.1016/j.jconrel.2024.04.051.
Yin W, Xu T, Ding H, Zhang J, Bodenko V, Tretyakova MS, Belousov MV, Liu Y, Oroujeni M, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A. (2023) Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. J Control Release 355, 515-527. doi: 10.1016/j.jconrel.2023.02.005.
Xu T, Ding H, Vorobyeva A, Oroujeni M, Orlova A, Tolmachev V, Gräslund T. (2021) Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Cancers. 13, 85. doi: 10.3390/cancers13010085.

Zelchan R, Chernov V, Medvedeva A, Rybina A, Bragina O, Mishina E, Larkina M, Varvashenya R, Fominykh A, Schulga A, Konovalova E, Vorobyeva A, Orlova A, Tashireva L, Deyev SM, Tolmachev V. (2024) Phase I Clinical Evaluation of Designed Ankyrin Repeat Protein [99mTc]Tc(CO)3-(HE)3-Ec1 for Visualization of EpCAM-Expressing Lung Cancer. Cancers 16(16), 2815. doi: 10.3390/cancers16162815.
Bragina O, Chernov V, Schulga A, Konovalova E, Garbukov E, Vorobyeva A, Orlova A, Tashireva L, Sörensen J, Zelchan R, Medvedeva A, Deyev S, Tolmachev V. (2022) Phase I trial of 99mTc-(HE)3-G3, a DARPin-based probe for imaging of HER2 expression. J Nucl Med. 2022;63:528-535. doi: 10.2967/jnumed.121.262542.
Bragina O, von Witting E, Garousi J, Zelchan R, Sandström M, Orlova A, Medvedeva A, Doroshenko A, Vorobyeva A, Lindbo S, Borin J, Tarabanovskaya N, Sorensen J, Hober S, Chernov V, Tolmachev V. (2021) Phase I study of 99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer. J Nucl Med 62(4):493-499. doi: 10.2967/jnumed.120.248799.